Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

0.2904 -0.0061 (-2.06%)
Official Closing Price Updated: 8:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 Next >
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
From CEL-SCI Corporation
Via Business Wire
TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Shares Replays of 2022 LD Micro Invitational Company Presentations
Via Investor Brand Network
CEL-SCI Corporation to Present at LD Micro Invitational
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Publication of ASCO 2022 Abstracts
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation (NYSE:CVM) Investor Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/07/2021 -- Certain directors of CEL-SCI Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation (NYSE:CVM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 07/13/2021 -- CEL-SCI Corporation is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.